iA Global Asset Management Inc. Buys 11,365 Shares of Quest Diagnostics Incorporated $DGX

iA Global Asset Management Inc. raised its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 13,215.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 11,451 shares of the medical research company’s stock after acquiring an additional 11,365 shares during the quarter. iA Global Asset Management Inc.’s holdings in Quest Diagnostics were worth $1,987,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. JFS Wealth Advisors LLC raised its holdings in Quest Diagnostics by 114.3% during the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after buying an additional 80 shares in the last quarter. Harbor Investment Advisory LLC raised its holdings in Quest Diagnostics by 113.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after buying an additional 83 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Quest Diagnostics during the third quarter valued at about $33,000. McIlrath & Eck LLC bought a new position in Quest Diagnostics during the fourth quarter valued at about $32,000. Finally, Wellington Shields Capital Management LLC bought a new position in Quest Diagnostics during the third quarter valued at about $38,000. 88.06% of the stock is currently owned by institutional investors.

Insider Transactions at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 2,628 shares of Quest Diagnostics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $204.86, for a total transaction of $538,372.08. Following the sale, the senior vice president directly owned 13,441 shares of the company’s stock, valued at $2,753,523.26. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Patrick Plewman sold 2,855 shares of Quest Diagnostics stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $588,729.55. Following the sale, the senior vice president directly owned 15,198 shares in the company, valued at approximately $3,133,979.58. This trade represents a 15.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 18,421 shares of company stock valued at $3,790,214 in the last ninety days. 0.88% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DGX shares. Robert W. Baird raised their target price on Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Saturday, April 25th. UBS Group raised their price target on Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, April 22nd. Finally, Evercore set a $225.00 price target on Quest Diagnostics in a research report on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.58.

Quest Diagnostics Trading Up 1.7%

Shares of NYSE:DGX opened at $189.87 on Tuesday. Quest Diagnostics Incorporated has a 52-week low of $164.65 and a 52-week high of $213.50. The company has a market cap of $21.02 billion, a P/E ratio of 20.98, a P/E/G ratio of 2.22 and a beta of 0.60. The stock’s 50-day moving average is $195.43 and its 200-day moving average is $190.07. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The business had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same period last year, the business earned $1.94 earnings per share. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Equities research analysts predict that Quest Diagnostics Incorporated will post 10.72 earnings per share for the current year.

Quest Diagnostics announced that its board has authorized a share repurchase program on Tuesday, February 10th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 4.7% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.